Literature DB >> 22189973

What is killing people with hepatitis C virus infection?

Jason Grebely1, Gregory J Dore.   

Abstract

The burden of hepatitis C virus (HCV)-related morbidity and mortality continues to rise. Progression to advanced liver disease among HCV-infected individuals generally requires decades, but we are entering an era where those infected with HCV in the 1970s and 1980s are at significant risk of mortality. Liver disease has overtaken drug-related harm as the major cause of mortality in HCV-infected individuals in many settings. Direct-acting antiviral therapies have provided renewed optimism, but HCV treatment uptake will need to increase markedly to reduce liver disease mortality. This review provides updated information on the natural history of HCV, disease-specific causes of mortality among people with HCV, estimates and projections of HCV-related disease burden and mortality and individual and population-level strategies to reduce mortality. The considerable variability in mortality rates within subpopulations of people with HCV will be outlined, such as in people who inject drugs and those with HIV co-infection. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189973     DOI: 10.1055/s-0031-1297922

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  44 in total

1.  Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.

Authors:  J Grebely; A Litwin; G J Dore
Journal:  J Viral Hepat       Date:  2016-06-08       Impact factor: 3.728

Review 2.  Future therapies for chronic hepatitis C.

Authors:  Noura M Dabbouseh; Donald M Jensen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

3.  Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui
Journal:  Addiction       Date:  2013-10-24       Impact factor: 6.526

4.  Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

Authors:  B Hajarizadeh; B Grady; K Page; A Y Kim; B H McGovern; A L Cox; T M Rice; R Sacks-Davis; J Bruneau; M Morris; J Amin; J Schinkel; T Applegate; L Maher; M Hellard; A R Lloyd; M Prins; R B Geskus; G J Dore; J Grebely
Journal:  J Viral Hepat       Date:  2015-01-08       Impact factor: 3.728

5.  Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital.

Authors:  Sunil Taneja; Sunil Tohra; Ajay Duseja; Radha Krishan Dhiman; Yogesh Kumar Chawla
Journal:  J Clin Exp Hepatol       Date:  2016-08-18

Review 6.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

7.  Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.

Authors:  Michael Gschwantler; Hermann Laferl; Wolfgang Vogel; Wolfgang Korak; Stephan Moser; Harald Hofer; Bernhard Bauer; Michael Schleicher; Barbara Bognar; Martin Bischof; Rudolf Stauber; Andreas Maieron; Peter Ferenci
Journal:  Wien Klin Wochenschr       Date:  2017-09-12       Impact factor: 1.704

8.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

9.  Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?

Authors:  Jason Grebely; Bridget Haire; Lynn E Taylor; Paul Macneill; Alain H Litwin; Tracy Swan; Jude Byrne; Jules Levin; Philip Bruggmann; Gregory J Dore
Journal:  J Hepatol       Date:  2015-08-04       Impact factor: 25.083

10.  The Second Canadian Symposium on hepatitis C virus: a call to action.

Authors:  Jason Grebely; Marc Bilodeau; Jordan J Feld; Julie Bruneau; Benedikt Fischer; Jennifer F Raven; Eve Roberts; Norma Choucha; Rob P Myers; Selena M Sagan; Joyce A Wilson; Frank Bialystok; D Lorne Tyrrell; Michael Houghton; Mel Krajden
Journal:  Can J Gastroenterol       Date:  2013-11       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.